The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p18,000.00. Justin Smith has given his Buy rating due to a combination of ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Senior Independent Non-Executive Director, Philip Broadley, has made a notable ...

Profit after tax came in ₹38.4 crore in Q2 of FY25, a recovery from a net loss of ₹11.8 crore in the first quarter of this ...

The FTSE 100 index is seen opening eight points higher at 8034, having fallen 1.2% to a three-month low in yesterday’s ...

AstraZeneca Plc isn’t the only health-care company facing compliance questions in China as concern continued to swirl about a ...

AstraZeneca records 50% share of gross profits on sales of Beyfortus in major ... partially offset by mandatory price ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...

Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...